AMAG Share Price

Open 33.15 Change Price %
High 34.50 1 Day 1.18 3.55
Low 32.90 1 Week 0.70 2.08
Close 34.40 1 Month 9.20 36.51
Volume 729359 1 Year 5.26 18.05
52 Week High 34.50
52 Week Low 17.92
AMAG Important Levels
Resistance 2 35.88
Resistance 1 35.27
Pivot 33.93
Support 1 33.53
Support 2 32.92
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SIRI 4.33 0.70%
SUSQ 14.20 -0.77%
AAPL 109.10 -0.73%
AAPL 109.10 -0.73%
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LLEN 0.03 50.00%
LOCM 0.09 50.00%
RITT 0.09 50.00%
MEMP 0.64 33.33%
SKBI 0.19 26.67%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
CLNT 0.88 23.94%
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LIWA 0.01 -50.00%
AMCF 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG)

AMAG Technical Analysis 5
As on 5th Dec 2016 AMAG Share Price closed @ 34.40 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 24.67 & Strong Buy for SHORT-TERM with Stoploss of 27.27 we also expect STOCK to react on Following IMPORTANT LEVELS.
AMAG Target for December
1st Target up-side 38.99
2nd Target up-side 43.04
3rd Target up-side 47.1
1st Target down-side 27.41
2nd Target down-side 23.36
3rd Target down-side 19.3
AMAG Other Details
Segment EQ
Market Capital 334970336.00
Sector Healthcare
Industry Diagnostic Substances
Offical website
AMAG Address
1100 Winter Street
Waltham, MA 02451
United States
Phone: 617-498-3300
Fax: 617-499-3361
Interactive Technical Analysis Chart AMAG Pharmaceuticals, Inc. ( AMAG NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on AMAG Pharmaceuticals, Inc.
AMAG Business Profile
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (IDA). The Company markets and sells Feraheme in the United States through its own commercial organization. Feraheme is approved for use in the treatment of both dialysis and non-dialysis dependent chronic kidney disease (CKD) patients. The Company’s principal source of revenue is from the sale of Feraheme (ferumoxytol) Injection for intravenous (IV). In December 2011, Feraheme was also granted marketing approval in Canada for use as an IV iron replacement therapy for the treatment of IDA in adult patients with CKD. GastroMARK, which is marketed and sold under the trade name Lumirem outside of the United States, is the Company’s oral contrast agent used for delineating the bowel in magnetic resonance imaging (MRI), and is approved and marketed in the United States, Europe, and other countries through its licensees. The Company markets and sells Feraheme in both the dialysis and non-dialysis CKD markets, including to nephrologists, hematologists, dialysis organizations, hospitals and other end-users who treat patients with CKD. There are two methods used to treat IDA in CKD patients: oral iron supplements and IV iron. Oral iron supplements are often not absorbed well by the gastrointestinal tract and frequently have unpleasant side effects, such as constipation, diarrhea, and cramping, which can cause patients to stop taking their medication. In addition, it can take an extended time for hemoglobin levels to improve the initiation of oral iron treatment.